Literature DB >> 29687414

M1 Macrophages but Not M2 Macrophages Are Characterized by Upregulation of CRP Expression via Activation of NFκB: a Possible Role for Ox-LDL in Macrophage Polarization.

Marielle Kaplan1, Anna Shur2, Yvgeny Tendler2.   

Abstract

Arterial macrophages comprise a heterogeneous population: pro-inflammatory (M1) and anti-inflammatory (M2). Since C-reactive protein (CRP) is produced by macrophages in atherosclerotic lesions, understanding of CRP regulation in macrophages could be crucial to decipher inflammatory patterns in atherogenesis. We aimed to analyze CRP expression in M1/M2 macrophages and to question whether it involves NFκB signaling pathway. Furthermore, we questioned whether oxidative stress affect macrophage phenotype and modulate macrophage CRP expression. M1/M2 macrophage polarization was validated using THP-1 macrophages. CRP mRNA and protein expression were determined using real-time PCR and immunohistochemistry. Involvement of NFκB was determined by nuclear translocation of p50 subunit and the use of NFκB inhibitor. Involvement of oxidative stress in macrophage phenotypes induction was studied using oxidized-LDL (Ox-LDL) and antioxidants. M1 macrophages were characterized by elevated CRP mRNA expression (by 67%), CRP protein levels (by 108%), and upregulation of NFκB activation compared to control, but these features were not shared by M2 macrophages. Macrophages incubation with Ox-LDL led to a moderate M1 phenotype combined with a M2 phenotype, correlated with increased CRP mRNA expression. Antioxidants inhibited by up to 86% IL6 expression but did not significantly affect IL10 secretion. Antioxidants significantly inhibited CRP expression in M1 macrophages, but not in M2 macrophages. Elevated expression of CRP was characteristic of M1 macrophages rather than M2 through NFκB activation. Oxidative stress could be one of the endogenous triggers for macrophage activation to a mixed M1 and M2 phenotype, in association with increased expression of CRP.

Entities:  

Keywords:  C-reactive protein; atherosclerosis; macrophages; oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 29687414     DOI: 10.1007/s10753-018-0793-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  49 in total

1.  Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris.

Authors:  Xiangjun Yang; Wenzhi Hu; Qin Zhang; Yueying Wang; Lie Sun
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-03-22       Impact factor: 4.080

2.  Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter.

Authors:  Bhavya Voleti; Alok Agrawal
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

3.  Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages.

Authors:  Bianca Fuhrman; Nina Volkova; Michael Aviram
Journal:  J Nutr Biochem       Date:  2005-09       Impact factor: 6.048

4.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

Authors:  M Amine Bouhlel; Bruno Derudas; Elena Rigamonti; Rébecca Dièvart; John Brozek; Stéphan Haulon; Christophe Zawadzki; Brigitte Jude; Gérard Torpier; Nikolaus Marx; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

Review 5.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

6.  Production of modified C-reactive protein in U937-derived macrophages.

Authors:  Irina Ciubotaru; Lawrence A Potempa; Rosemary C Wander
Journal:  Exp Biol Med (Maywood)       Date:  2005-11

7.  Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation.

Authors:  Tetsunori Ishikawa; Takuroh Imamura; Kinta Hatakeyama; Haruhiko Date; Toshiro Nagoshi; Riichirou Kawamoto; Akihiko Matsuyama; Yujiro Asada; Tanenao Eto
Journal:  Am J Cardiol       Date:  2004-03-01       Impact factor: 2.778

8.  Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia.

Authors:  Alexander Kovacs; Per Tornvall; Roland Nilsson; Jesper Tegnér; Anders Hamsten; Johan Björkegren
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

9.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries.

Authors:  J Torzewski; M Torzewski; D E Bowyer; M Fröhlich; W Koenig; J Waltenberger; C Fitzsimmons; V Hombach
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-09       Impact factor: 8.311

10.  Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris.

Authors:  Tetsunori Ishikawa; Kinta Hatakeyama; Takuroh Imamura; Haruhiko Date; Yoshisato Shibata; Yutaka Hikichi; Yujiro Asada; Tanenao Eto
Journal:  Am J Cardiol       Date:  2003-02-01       Impact factor: 2.778

View more
  4 in total

Review 1.  Possible roles of anti-type II collagen antibody and innate immunity in the development and progression of diabetic retinopathy.

Authors:  Tsunehiko Ikeda; Kimitoshi Nakamura; Teruyo Kida; Hidehiro Oku
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-11       Impact factor: 3.535

2.  Therapeutic Effect of Schistosoma japonicum Cystatin on Atherosclerotic Renal Damage.

Authors:  Huijuan Yang; Hongqi Li; Weidong Chen; Zhijie Mei; Yuan Yuan; Xiaoli Wang; Liang Chu; Yu Xu; Yan Sun; Dingru Li; Hongyu Gao; Bin Zhan; Huihui Li; Xiaodi Yang
Journal:  Front Cell Dev Biol       Date:  2021-11-25

Review 3.  A Bibliometric and Knowledge-Map Analysis of Macrophage Polarization in Atherosclerosis From 2001 to 2021.

Authors:  Luxia Song; Jie Zhang; Dan Ma; Yixuan Fan; Runmin Lai; Wende Tian; Zihao Zhang; Jianqing Ju; Hao Xu
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

Review 4.  Macrophage-Based Therapies for Atherosclerosis Management.

Authors:  Renyi Peng; Hao Ji; Libo Jin; Sue Lin; Yijiang Huang; Ke Xu; Qinsi Yang; Da Sun; Wei Wu
Journal:  J Immunol Res       Date:  2020-01-29       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.